Genprex Inc GNPX Stock Analysis

About Genprex Inc

Genprex, Inc. is a clinical-stage gene therapy company focusing on developing innovative treatments designed to restore biological functions disrupted by disease. The Company's lead oncology program, Reqorsa ® (quaratusugene ozeplasmid), a gene therapy product, is being developed for the treatment of lung cancer and is designed to deliver the TUSC2 tumor suppressor gene to help restore tumor-suppressive activity and address multiple pathways involved in cancer progression. The Company's lead candidate, REQORSA ® uses the systemic, non-viral ONCOPREX ® Delivery System to deliver the TUSC2 tumor suppressor gene via a non-viral lipid-based nanoparticle. REQORSA is designed to restore tumor-suppressor function and is being evaluated in the Acclaim-1 and Acclaim-3 clinical trials for non-small cell lung cancer and small cell lung cancer, respectively. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to both lung cancer programs and Orphan Drug designation to the small cell lung cancer program. Genprex is also advancing an earlier stage gene therapy program for diabetes, designed to restore insulin-producing capability through the expression of key pancreatic transcription factors. Across its programs, Genprex is focused on translating innovative gene therapy approaches into meaningful therapeutic advances for patients with significant unmet medical needs.